Drugs / monosialic gangliosides
monosialic gangliosides
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04538833 | Sep 2020 → Aug 2022 | female breast carcinoma | Henan Cancer Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT04222790 | Aug 2020 → Apr 2022 | female breast carcinoma | Henan Cancer Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | monosialic gangliosides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04538833 ↗ |
| Known as | GM1 | “Monosialoganglioside (GM1), a member of the ganglioside family, is a kind of glycosylsphingolipid containing sialic acid on the cell membrane of mammalian animals.” NCT04222790 ↗1“The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).” NCT04538833 ↗ |
| Known as | Monosialoganglioside | “Monosialoganglioside (GM1), a member of the ganglioside family, is a kind of glycosylsphingolipid containing sialic acid on the cell membrane of mammalian animals.” NCT04222790 ↗ |